Cargando…

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

BACKGROUND: ADVANCE was a phase III trial of the efficacy and safety of subcutaneous peginterferon beta-1a 125 µg every 2 or 4 weeks in patients with relapsing-remitting multiple sclerosis (RRMS). ATTAIN was a 2-year extension study of ADVANCE. The aim was to evaluate the long-term safety, tolerabil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Newsome, Scott D., Scott, Thomas F., Arnold, Douglas L., Nelles, Gereon, Hung, Serena, Cui, Yue, Shang, Shulian, Naylor, Maria L., Kremenchutzky, Marcelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113734/ https://www.ncbi.nlm.nih.gov/pubmed/30181778 http://dx.doi.org/10.1177/1756286418791143

Ejemplares similares

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis
por: Newsome, Scott D., et al.
Publicado: (2016)

Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis
por: Scott, Thomas F, et al.
Publicado: (2016)

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis
por: Arnold, Douglas L., et al.
Publicado: (2018)

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE
por: Kieseier, Bernd C, et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
por: Hu, Xiao, et al.
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
por: Hu, Xiao, et al.
Publicado: (2015)

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
por: Hu, Xiao, et al.
Publicado: (2016)

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis
por: Arnold, Douglas L, et al.
Publicado: (2014)

Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial
por: Arnold, Douglas L., et al.
Publicado: (2017)

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate
por: Scott, Thomas F., et al.
Publicado: (2021)

Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis
por: Hu, Xiao, et al.
Publicado: (2017)

Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach
por: White, Sarah, et al.
Publicado: (2021)

Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study
por: Arnold, Douglas L., et al.
Publicado: (2017)

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
por: Hendin, Barry, et al.
Publicado: (2018)

Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers
por: Zhao, Yuan, et al.
Publicado: (2021)

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
por: Kolb-Mäurer, Annette, et al.
Publicado: (2019)

Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study
por: Menge, Til, et al.
Publicado: (2021)

Versorgungsprojekt NPPV auf der Zielgeraden
por: Nelles, Gereon
Publicado: (2021)

Bekannte und neue Köpfe in Nordrhein
por: Nelles, Gereon
Publicado: (2022)

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2013)

Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations
por: Arnold, Douglas L, et al.
Publicado: (2015)

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C
por: Pouresmaeeli, Mahdiyar, et al.
Publicado: (2015)

Elasomeran/peginterferon: Autoimmune hepatitis: case report
Publicado: (2022)

A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
por: Xiao, Nan, et al.
Publicado: (2010)

Early Aggressive Treatment Approaches for Multiple Sclerosis
por: Simpson, Alexandra, et al.
Publicado: (2021)

Era of COVID-19 in Multiple Sclerosis Care
por: Krett, Jonathan D., et al.
Publicado: (2023)

Occupational Attainment as a Marker of Cognitive Reserve in Multiple Sclerosis
por: Ghaffar, Omar, et al.
Publicado: (2012)

Prediction of Treatment Week Eight Response & Sustained Virologic Response in Patients Treated with Boceprevir Plus Peginterferon Alfa and Ribavirin
por: Thompson, Alex, et al.
Publicado: (2014)

Prevention of Dementia: Focus on Lifestyle
por: Polidori, Maria Cristina, et al.
Publicado: (2010)

Multiple sclerosis and COVID-19: A great opportunity for databases promoting research and collaboration
por: Racke, Michael K., et al.
Publicado: (2020)

Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C
por: Kuo, Ming-Te, et al.
Publicado: (2014)

Peginterferon based therapy for chronic hepatitis C in the elderly patients
por: Bold, Adriana, et al.
Publicado: (2013)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Venocentric Lesions: An MRI Marker of MS?
por: Quinn, Matthew P., et al.
Publicado: (2013)

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis
por: Druyts, Eric, et al.
Publicado: (2012)

Treatment of chronic hepatitis D with peginterferon lambda—the phase 2 LIMT-1 clinical trial
por: Etzion, Ohad, et al.
Publicado: (2023)

Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era
por: Coyle, Patricia K., et al.
Publicado: (2021)

Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients
por: Hang, Yaming, et al.
Publicado: (2016)

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
por: Sonneveld, Milan J., et al.
Publicado: (2010)

Beta-Lactam Probability of Target Attainment Success: Cefepime as a Case Study
por: Selig, Daniel J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4d05s9r31gfmuf2mbvf2dt8evh